MedTrace Logo

Atrial Fibrillation with Heart Failure with Preserved Ejection Fraction: Treatment Strategies-Catheter Ablation Vs. Anti-Atrial Arrhythmia Drugs

NCT06740539 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2024-12-18

No results posted yet for this study

Summary

A comparison of whether catheter ablation improves the prognosis (all-cause mortality and/or the composite endpoint of MACE) and reduces the recurrence rate of atrial fibrillation (AF) in patients with AF and heart failure with preserved ejection fraction (HFpEF), compared to anti-atrial arrhythmia drugs (AAD). This trial was randomly divided into two groups: the anti-AAD drug group and the catheter ablation group.

Conditions

  • HFpEF - Heart Failure with Preserved Ejection Fraction
  • Atrial Fibrillation (AF)

Interventions

PROCEDURE

Catheter ablation of atrial fibrillation

Catheter ablation of atrial fibrillation

Sponsors & Collaborators

  • The Third Affiliated Hospital of Anhui Medical University

    collaborator UNKNOWN

  • Hefei Second People's Hospital

    collaborator UNKNOWN

  • The Second People's Hospital of Anhui Province

    collaborator OTHER

  • Hefei Binhu Hospital

    collaborator OTHER

  • Shanghai Chest Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2027-01-01
Completion
2027-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06740539 on ClinicalTrials.gov